Home › Acute Myeloid Leukemia › NCT07771803
A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients with relapsed or refractory AML or MM not on any anti-neoplastic therapy who have exhausted all therapies and have no available therapy. * For AML: Quantifiable leukemia cells in blood (patients without circulating AML blasts may participate if they agree to baseline and post-treatment bone marrow testing) * For MM: Quantifiable M component (SPEP) or serum free light chain abnormality (ratio greater than 10) * ECOG PS 0,1, or 2 * ALT, AST less than 3 times ULN * Bilirubin (total) \< 2.5 mg/dL * Renal function - estimated GFR \> 40 ml/min * No uncontrolled/active infections * Negative pregnancy test if of childbearing potential * No chronic neurologic disorders (peripheral neuropathy \> grade 2; Parkinson's disease; Alzheimer's disease; other neurologic diseases will be discussed with the PI) Exclusion Criteria: * Inability to understand the study procedures * Inability to understand the consent form --Pregnancy, breastfeeding, or inability or unwillingness to use effective contraception
About the study
Purpose/Specific Aims
The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop).
The study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed/refractory AML or MM for whom there are no standard therapeutic options.
What is being tested
- Soursop tea (biological)
Sponsor: Roger Strair · Participants: 20 · Started: Jun 30, 2025
Contact the study team
- John Riehman-Murphy, RN · Phone: 215-756-2772
- Roseann Freitag · Phone: 856-325-6733
Official record on ClinicalTrials.gov — NCT07771803
Locations in the U.S.
| New Jersey | MDA at Cooper University Health Care, Camden |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.